Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.

Swiss generic and biosimilar medicines major Sandoz today announced that the European Commission (EC) has granted marketing ...

Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

Statement/Regulatory AdmissionAflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA15-Nov-2024 / 18:18 CET/CESTDisclosure of an inside information acc. to Article ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...

Regeneron Pharmaceuticals (REGN) stock falls despite Q3 beat, a move attributed to lower-than-expected sales for its high-dose Eylea therapy. Read more here.

Since then, the company suffered litigation setbacks on Eylea and Amgen (AMGN) said this week that it had launched a biosimilar version of Eylea 2mg without waiting for the outcome of Regeneron's ...

Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns ...

Swiss stocks tumbled on Friday, weighed down data showing a slowdown in growth, and uncertainty about Fed interest rate cuts ...

https://www.tipranks.com/news/company-announcements/ceribell-inc-reports-strong-q3-2024-growth Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg ...